Arcturus Therapeutics Holdings Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on September 23, 2026. The filing discloses that the company presented an overview of Phase 2 clinical data for its candidate ARCT-810. Additionally, the company provided an update regarding its mRNA delivery platform during the presentation.
The filing states that Arcturus issued a press release summarizing the presentation. The company has incorporated the presentation and the press release as Exhibits 99.1 and 99.2, respectively, into this report.
The registrant is a Delaware corporation with its principal executive offices located at 10285 Science Center Drive in San Diego, California. The company’s common stock trades on The Nasdaq Stock Market LLC under the ticker symbol ARCT.
